Following Vraylar success, AbbVie extends partnership with Gedeon Richter to neuropsychiatric diseases
AbbVie is seeing dollar signs as it looks to expand the label on Vraylar, its Gedeon Richter-partnered antipsychotic blockbuster. And now, it wants to know what else the Hungarian pharma company has up its sleeve.
After seeing some preclinical results from Richter, AbbVie has extended its collaboration with the company to include new dopamine receptor modulators for neuropsychiatric diseases. The deal, unveiled Friday, will include “several new chemical entities,” though the partners seem to be keeping the financial terms under wraps.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.